WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion

European Journal of Pharmacology
A VicenticL D Van de Kar

Abstract

Previous studies suggest that the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) increases the secretion of oxytocin, adrenocorticotropic hormone (ACTH), corticosterone and prolactin but not renin. However, the lack of selective 5-HT1A receptor antagonists made it difficult to confirm that 5-HT1A receptors mediate the neuroendocrine responses to 8-OH-DPAT. This study investigated the effects of increasing doses of a selective 5-HT1A receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide (WAY-100635) on neuroendocrine responses induced by the 5-HT1A receptor agonist 8-OH-DPAT in adult male rats. 8-OH-DPAT, 500 microg/kg s.c., increased plasma levels of oxytocin (to 970% above basal levels); ACTH (to 1622% above basal levels), corticosterone (to 458% above basal levels) and prolactin (to 313% above basal levels), but not renin. The lowest dose of WAY-100635 (0.1 mg/kg s.c.) significantly inhibited the 8-OH-DPAT-induced increase in plasma oxytocin but not ACTH or corticosterone levels. At a dose of 1 mg/kg (s.c.), WAY-100635 completely blocked the oxytocin and ACTH responses and maximally inhibited the corticosterone response to 8-OH-DPAT, although co...Continue Reading

References

Jan 1, 1990·Journal of Cardiovascular Pharmacology·H DabiréH Schmitt
Jan 1, 1989·Pflügers Archiv : European journal of physiology·H EhmkeH Kirchheim
Jun 1, 1988·Regulatory Peptides·T TakaoZ Ota
Mar 15, 1988·European Journal of Pharmacology·F GilbertS M Stahl
Feb 9, 1988·European Journal of Pharmacology·C S AulakhD L Murphy
Jul 28, 1988·The New England Journal of Medicine·A L Taylor, L M Fishman
Oct 27, 1980·Life Sciences·I Cavero, A G Roach
Feb 14, 1995·European Journal of Pharmacology·A D LevyL D Van de Kar
Aug 1, 1994·Neuroendocrinology·P A RittenhouseL D van de Kar
Jun 24, 1993·European Journal of Pharmacology·A FletcherY Reilly
Jul 25, 1995·European Journal of Pharmacology·E A ForsterA Fletcher
Oct 1, 1996·Pharmacology, Biochemistry, and Behavior·L GroeninkB Olivier
Apr 1, 1997·Hypertension·I YamaguchiR A Felder

❮ Previous
Next ❯

Citations

Jun 2, 2005·Pharmacology, Biochemistry, and Behavior·M P ViverosSandra E File
Apr 12, 2001·Biological Psychiatry·T PattijB Olivier
Dec 13, 2000·Pharmacology, Biochemistry, and Behavior·R L CommissarisD H Overstreet
Dec 14, 2002·Pharmacology, Biochemistry, and Behavior·F MirandaD N Velázquez-Martínez
Jul 28, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H H Berendsen, C L Broekkamp
Nov 19, 2013·Pharmacology, Biochemistry, and Behavior·Eelke M S SnoerenRonald S Oosting
Nov 2, 2014·The Journal of Sexual Medicine·Trynke R de Jong, Inga D Neumann
Jan 20, 2007·The Journal of Sexual Medicine·Trynke R de JongMarcel D Waldinger
May 12, 2009·Behavioural Brain Research·Murilo Marcos Dos SantosJosé Marino-Neto
Jul 9, 2004·Annals of the New York Academy of Sciences·Jens D MikkelsenAlexander Kiss
Aug 2, 2011·Journal of Neuroscience Research·Claire-Marie VacherHélène Hardin-Pouzet
Dec 20, 2005·Brain Research·Juliana Irani Fratucci De GobbiJosé Vanderlei Menani
Aug 5, 2014·European Journal of Pharmacology·J G VeeningB Olivier
May 17, 2015·Neuroscience and Biobehavioral Reviews·A Rubio-CasillasA Fernández-Guasti
Feb 3, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Donatella MarazzitiMario Catena-Dell'Osso
Dec 3, 2014·European Journal of Pharmacology·Donald R Gehlert, Janice Shaw
May 6, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Isabella PacchiarottiEduard Vieta
Apr 29, 2008·The Psychiatric Clinics of North America·Jelena BrezoGustavo Turecki
Oct 25, 2016·Hormones and Behavior·Rebecca H LarkeKaren L Bales
Feb 11, 2004·The Journal of Pharmacology and Experimental Therapeutics·Patrick Osei-Owusu, Karie E Scrogin
Apr 6, 2004·The Journal of Pharmacology and Experimental Therapeutics·Yahong ZhangLouis D Van de Kar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.